JPX · 4564.T
OncoTherapy Science, Inc.
¥18+¥1 (+5.88%)
OncoTherapy Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
Loading market information…
JPX · 4583.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Chiome Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Chiome Bioscience Inc.’s next earnings report is currently expected on Nov 10, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Chiome Bioscience Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib System, a technology for generating monoclonal antibodies which is used to generate antibodies for drug discovery research; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. It also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody production; and antibody generation services using the ADLib system. In addition, the company's product pipeline under Phase 1 trial comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer (TNBC). Further, its product pipeline under preclinical study includes PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC; BMAA, an anti-semphorin3a antibody for treating renal and other diseases; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; PFKR, an anti-CX3CR1 antibody for secondary progressive multiple sclerosis; and PXLR, an anti-CXCL1/2/3/5 antibody for the treatment of gastric, breast, and ovarian tumors. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥18+¥1 (+5.88%)
OncoTherapy Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
¥403-¥16 (-3.82%)
J-Pharma Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.19% below the high.
¥800-¥1 (-0.12%)
ADR120S, Inc.’s quoted price sits in the lower half of its reported 52-week range, 10.11% below the high.
¥701-¥6 (-0.85%)
StemCell Institute Inc.’s quoted price sits in the lower half of its reported 52-week range, 28.18% below the high.
¥135-¥1 (-0.74%)
TMS Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.18% below the high.
¥20-¥1 (-4.76%)
MEDINET Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.72% below the high.
¥40-¥1 (-2.44%)
BrightPath Biotherapeutics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
¥200+¥2 (+1.01%)
Linical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.34% below the high.
